Grubar J C, Gigli G L, Colognola R M, Ferri R, Musumeci S A, Bergonzi P
Psychopharmacology (Berl). 1986;90(1):119-22. doi: 10.1007/BF00172882.
Several investigators have described the altered sleep patterns in Down's syndrome subjects. The most relevant findings have been a reduction in percentage of REM sleep, a prolonged latency to the first REM episode, an increase in undifferentiated sleep, and a reduced ratio of the oculomotor frequencies. Because it is of interest to identify new drugs able to increase the percentage of REM sleep in mentally retarded subjects, we studied the effects of butoctamide hydrogen succinate (BAHS) on nocturnal sleep in eight young institutionalized Down's syndrome subjects. BAHS produced a significant increase in the percentage of REM sleep as well as a decrease in undifferentiated sleep and latency to the first REM.
几位研究人员描述了唐氏综合征患者睡眠模式的改变。最相关的发现是快速眼动睡眠百分比降低、首次快速眼动发作的潜伏期延长、无差别的睡眠增加以及动眼频率比值降低。由于确定能够提高智障患者快速眼动睡眠百分比的新药很有意义，我们研究了丁辛酰胺琥珀酸氢盐（BAHS）对8名住在福利院的年轻唐氏综合征患者夜间睡眠的影响。BAHS使快速眼动睡眠百分比显著增加，同时无差别的睡眠和首次快速眼动的潜伏期减少。
